|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 307.59 USD | +0.77% |
|
+1.62% | +4.77% |
| 07-03 | Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals | MT |
| 06-25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
| Market Cap | 49.4B 56.51B 45.4B 42.32B 80.26B 5,380B 81.48B 545B 212B 2,645B 212B 208B 9,113B | P/E 2026 * |
28x | P/E 2027 * | 22x |
|---|---|---|---|---|---|
| Enterprise Value | 49.13B 56.2B 45.15B 42.08B 79.82B 5,351B 81.03B 542B 211B 2,630B 211B 206B 9,063B | EV / Sales 2026 * |
5.76x | EV / Sales 2027 * | 4.89x |
| Free-Float |
61.59% | Yield 2026 * |
0.56% | Yield 2027 * | 0.58% |
Last Transcript: UCB
| 1 day | +0.77% | ||
| 1 week | +1.62% | ||
| Current month | -1.93% | ||
| 1 month | -1.11% | ||
| 3 months | +0.73% | ||
| 6 months | +8.74% | ||
| Current year | +4.77% |
| 1 week | 302.48 |  | 313.64 |
| 1 month | 279.16 | | 321.05 |
| Current year | 266.62 | | 345.39 |
| 1 year | 194.76 | | 345.39 |
| 3 years | 69.7 | | 345.39 |
| 5 years | 68.3 | | 345.39 |
| 10 years | 58.42 | | 345.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 30/06/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.77% | +1.62% | - | - | 56.51B | |
| +4.73% | +3.38% | +19.53% | -8.89% | 66.56B | |
| +1.07% | +42.10% | +42.10% | +42.10% | 42.98B | |
| +3.45% | +6.04% | -49.82% | -55.95% | 40.46B | |
| +3.04% | +0.04% | +62.66% | -24.29% | 31.91B | |
| +10.01% | +18.57% | +161.59% | -34.48% | 31.65B | |
| +2.68% | +2.73% | +70.72% | +88.24% | 23.35B | |
| +2.87% | +16.83% | +1.86% | +165.26% | 19.46B | |
| -0.13% | +2.75% | +66.32% | +127.01% | 17.18B | |
| +3.58% | +9.89% | +75.47% | +344.90% | 15.12B | |
| Average | +3.21% | +9.91% | +50.05% | +71.55% | 32.07B | |
| Weighted average by Cap. | +3.27% | +8.85% | +42.18% | +33.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.53B 9.76B 7.84B 7.31B 13.86B 929B 14.08B 94.15B 36.6B 457B 36.64B 35.85B 1,574B | 9.63B 11.02B 8.85B 8.25B 15.65B 1,049B 15.89B 106B 41.32B 516B 41.37B 40.48B 1,777B |
| Net income | 1.75B 2B 1.61B 1.5B 2.84B 190B 2.88B 19.28B 7.49B 93.55B 7.5B 7.34B 322B | 2.26B 2.59B 2.08B 1.94B 3.68B 247B 3.73B 24.98B 9.71B 121B 9.72B 9.51B 418B |
| Net Debt | -271M -310M -249M -232M -441M -29.55B -447M -2.99B -1.16B -14.52B -1.16B -1.14B -50.05B | -2.31B -2.65B -2.13B -1.98B -3.76B -252B -3.82B -25.52B -9.92B -124B -9.93B -9.72B -427B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/07/26 | US$307.59 | +0.77% | 190 |
| 01/07/26 | US$305.24 | -2.68% | 10 |
| 30/06/26 | US$313.64 | +1.08% | 1 |
| 29/06/26 | US$310.29 | +2.51% | 36 |
| 26/06/26 | US$302.69 | +2.01% | 17 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
- UCBJF Stock
Select your edition
All financial news and data tailored to specific country editions
